Pandorum Technologies Secures $11 Million Investment to Advance its Regenerative Therapy for Corneal Blindness to Clinical Phase

Pandorum Technologies announced the closure of a pre-Series B funding round, securing $11 million in investment to progress toward the first-in-human study of its flagship product, Kuragenx ("Liquid Cornea") to treat corneal blindness. The funding will also allow the company to advance its tunable technology platform that has demonstrated regenerative potential beyond cornea, such as for liver, lung and neuronal tissues.

Founded by Arun Chandru & Dr. Tuhin Bhowmick, the startup company focuses on Tissue Engineering and Regenerative Medicine. The funding was sourced from Ashish Kacholia, Everest Finance Investment, Acebright Pharma, and Bandana Kankani's syndicate, along with existing investors Sunil Kant Munjal and the Indian Angel Network.

"We are thrilled to have the support of the notable investors, including Mr. Ashish Kacholia, as we continue to innovate and develop therapeutics to restore healthy tissue functions, in order to help the patients suffering from unmet clinical needs. Our flagship product Kuragenx combines proprietary biomaterials with regenerative nanotherapy, guiding the formation of a functional corneal tissue to restore vision. This is a first-in-class approach that can truly blur the line between treatment and cure," Dr. Bhowmick, Co-Founder & CEO of Pandorum Technologies, said in a company news release.

Pandorum's Kuragenx promotes scarless regeneration of cornea tissue to restore vision, as demonstrated in pre-clinical studies. In 2023, Kuragenx was awarded the Orphan Drug Designation by the FDA for the treatment of neurotrophic keratitis. Pandorum is currently engaged in clinical manufacturing process and IND enabling studies of Kuragenx, with the aim toward the first patient dosing in 2025, after obtaining due regulatory approvals.